# Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Study · id `cardio:ct-nct01970501` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01970501](<https://clinicaltrials.gov/study/NCT01970501>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01970501

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.

## Technical summary

Registry record NCT01970501. Randomized; quadruple masking; primary purpose treatment. Start 2014-04 (registry gives no type); primary completion 2017-12-28 (actual). Results posted on 2022-09-15.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 267 participants (enrolled count; ClinicalTrials.gov record NCT01970501, source copy `cardio:ctgov-nct01970501-2022-09-26`, retrieved 2026-10-26)
- Start date: 2014-04 (registry gives no type) (ClinicalTrials.gov record NCT01970501, source copy `cardio:ctgov-nct01970501-2022-09-26`, retrieved 2026-10-26)
- Primary completion: 2017-12-28 (actual) (ClinicalTrials.gov record NCT01970501, source copy `cardio:ctgov-nct01970501-2022-09-26`, retrieved 2026-10-26)
- Completion: 2017-12-28 (actual) (ClinicalTrials.gov record NCT01970501, source copy `cardio:ctgov-nct01970501-2022-09-26`, retrieved 2026-10-26)
- Results first posted: 2022-09-15 (ClinicalTrials.gov record NCT01970501, source copy `cardio:ctgov-nct01970501-2022-09-26`, retrieved 2026-10-26)
- Countries: United States; Canada; Hungary; Netherlands; Poland; Serbia (ClinicalTrials.gov record NCT01970501, source copy `cardio:ctgov-nct01970501-2022-09-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01970501-2022-09-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
- Acronym: GENETIC-AF
- Condition: Current or Recent History of Atrial Fibrillation
- Intervention (Drug): bucindolol hydrochloride
- Intervention (Drug): metoprolol succinate
- Intervention (Other): Placebo oral capsule
- Lead sponsor: ARCA Biopharma, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Medtronic
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as a collaborator: Medtronic (`cardio:medtronic`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype (`cardio:pubmed-34270905`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d943c71a81c962078c01e9ee2a1ccdd32e9580ce0d8f506b566cc3dcb50ad886
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
